Vimovo Lawsuit

The ingredients in Vimovo include a proton pump inhibitor which has been linked to serious kidney complications, including acute interstitial nephritis, chronic kidney disease and kidney failure.

Vimovo Lawsuit Reviews

The nationwide law firm of Bernstein Liebhard LLP is now investigating Vimovo lawsuits on behalf of patients who may have suffered serious kidney complications related to its use, including:

  • Acute interstitial nephritis
  • Chronic kidney disease
  • Kidney failure
  • Renal impairment

To learn more, please contact our office today at (888) 994-5118.

Vimovo and the Kidneys

Vimovo is an anti-arthritic that contains the painkiller naproxen, as well as esomeprazole, a proton pump inhibitor that is the active ingredient in Nexium.  Naproxen is known to be substantially excreted by the kidneys, and the Vimovo label warns that the risk of toxic reactions to the drug may be greater in patients with impaired renal function.  The label also notes that the risk of Vimovo kidney problems increases for elderly patients, especially those with decreased kidney function. Doctors are advised to monitor kidney function and carefully choose the starting dose.

In 2014, the U.S. Food & Drug Administration (FDA) added information about acute interstitial nephritis to the labels of all prescription proton pump inhibitors, including Vimovo. This hypersensitivity reaction causes a sudden inflammation of the kidney tubules, and can lead to chronic kidney disease and kidney failure if not treated promptly. Symptoms of this potentially dangerous condition include:

  • Blood in the urine
  • Fever
  • Changes in urine output
  • Drowsiness or confusion
  • Nausea, vomiting
  • Rash
  • Swelling of the body
  • Weight gain from fluid-retention

Studies Link Proton Pump Inhibitors to Kidney Complications

In recent years, research has suggested that proton pump inhibitors could potentially harm the kidneys, especially if they are used for extended period of time.

In April 2015, a study published in CMAJ Open that involved 290,000 people found that those using proton pump inhibitors faced a 3-fold increased risk of nephritis, as well as a 2.4-fold increased risk of acute kidney injury. A little over a year later, a paper published in JAMA: Internal Medicine reported that kidney failure occurred in 15-to-46% of subjects using proton pump inhibitors.  That study drew data from medical records involving more than 10,500 people.

In April 2016, scientists writing in the Journal of the American Society of Nephrology reported that people who took proton pump inhibitors had a 96% increased risk of kidney failure and a 26% increased risk of chronic kidney disease compared to patient using another type of heartburn drug. After five years of follow-up, 15% of the proton pumps inhibitor patients had been diagnosed with kidney disease versus just 11% of those taking the other drugs. Kidney failure was twice as common among proton pump inhibitor users, though the rate in both groups was low overall. Those who took the medications for 1 to 2 years were three times more likely to develop kidney failure compared to those who only took proton pump inhibitors for a couple of months.

Learn More about Filing a Vimovo Lawsuit

You may be eligible to file a Vimovo lawsuit if you or a loved one were diagnosed with nephritis, kidney failure or chronic kidney disease while taking this medication. To obtain a free, no-obligation review of your case, please call (888) 994-5118.

  1. Horizon Pharma (2016) “Vimovo: Highlight of Prescribing Information”
  2. FDA (2015) “Vimovo (naproxen/esomeprazole magnesium) tablets”
  3. CMAJ Open (2015) “Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study”
  4. JAMA: Internal Medicine (2016) “Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease”
  5. JASN (2016) “Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD”
Last Modified: June 14, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content